Unnamed: 0,title,date,stock,sentiment
1078371.0,"The Daily Biotech Pulse: Co-Diagnostics Earnings, NantKwest Plans Pancreatic Cancer Study, ADC Therapeutics IPO",2020-05-15 07:49:00-04:00,REPH,negative
1078372.0,Stocks That Hit 52-Week Lows On Thursday,2020-05-14 10:47:00-04:00,REPH,negative
1078373.0,"The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger",2020-05-14 08:32:00-04:00,REPH,positive
1078374.0,"Shares of several companies in the broader healthcare sector are trading lower amid market weakness despite recent strength from many names in the space. Equities are down for the session following cautious comments from US Fed Chair Powell, which forecast uncertainty and downside risk. Some regions of the US have extended lockdown restrictions, including Washington D.C.  and Los Angeles County.",2020-05-13 12:49:00-04:00,REPH,negative
1078375.0,Stocks That Hit 52-Week Lows On Wednesday,2020-05-13 11:07:00-04:00,REPH,negative
1078376.0,"Oppenheimer Maintains Outperform on Recro Pharma, Lowers Price Target to $12",2020-05-12 08:20:00-04:00,REPH,negative
1078377.0,"The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings",2020-05-12 08:06:00-04:00,REPH,negative
1078378.0,78 Biggest Movers From Yesterday,2020-05-12 05:02:00-04:00,REPH,neutral
1078379.0,Mid-Afternoon Market Update: NASDAQ Rises Over 100 Points; Amneal Pharmaceuticals Shares Surge On Upbeat Results,2020-05-11 15:02:00-04:00,REPH,positive
1078380.0,54 Stocks Moving In Monday's Mid-Day Session,2020-05-11 12:39:00-04:00,REPH,neutral
1078381.0,Mid-Day Market Update: Recro Pharma Falls After Q1 Results; MyoKardia Shares Climb,2020-05-11 12:29:00-04:00,REPH,positive
1078382.0,Stocks That Hit 52-Week Lows On Monday,2020-05-11 10:43:00-04:00,REPH,negative
1078383.0,Mid-Morning Market Update: Markets Mostly Lower; Cardinal Health Beats Q3 Estimates,2020-05-11 10:15:00-04:00,REPH,negative
1078384.0,Recro Pharma shares are trading lower after the company reported worse-than-expected Q1 EPS and sales results.,2020-05-11 09:07:00-04:00,REPH,neutral
1078385.0,15 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-05-11 07:36:00-04:00,REPH,neutral
1078386.0,Recap: Recro Pharma Q1 Earnings,2020-05-11 07:31:00-04:00,REPH,neutral
1078387.0,"Recro Pharma Q1 EPS $(0.330) Misses $(0.030) Estimate, Sales $21.777M Beat $19.450M Estimate",2020-05-11 07:16:00-04:00,REPH,negative
1078388.0,"The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight",2020-05-10 15:40:00-04:00,REPH,neutral
1078389.0,80 Biggest Movers From Yesterday,2020-03-31 04:15:00-04:00,REPH,neutral
1078390.0,55 Stocks Moving In Monday's Mid-Day Session,2020-03-30 12:49:00-04:00,REPH,neutral
1078391.0,Mid-Day Market Update: Dow Jumps Over 400 Points; Plus Therapeutics Shares Spike Higher,2020-03-30 12:41:00-04:00,REPH,positive
1078392.0,"Stephens & Co. Maintains Overweight on Recro Pharma, Lowers Price Target to $18",2020-03-05 10:21:00-05:00,REPH,negative
1078393.0,92 Biggest Movers From Yesterday,2020-03-05 04:41:00-05:00,REPH,neutral
1078394.0,Mid-Afternoon Market Update: Dow Jumps Over 800 Points; Cardlytics Shares Slide,2020-03-04 14:30:00-05:00,REPH,positive
1078395.0,Afternoon Market Stats In 5 Minutes,2020-03-04 14:14:00-05:00,REPH,neutral
1078396.0,60 Stocks Moving In Wednesday's Mid-Day Session,2020-03-04 12:11:00-05:00,REPH,neutral
1078397.0,Mid-Day Market Update: Owens & Minor Falls On Weak Sales; Cellect Biotechnology Shares Climb,2020-03-04 12:02:00-05:00,REPH,negative
1078398.0,Mid-Morning Market Update: Markets Open Higher; Dollar Tree Posts Mixed Q4 Results,2020-03-04 10:20:00-05:00,REPH,neutral
1078399.0,"The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies",2020-03-04 07:37:00-05:00,REPH,negative
1078400.0,"The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering",2020-02-14 08:23:00-05:00,REPH,negative
1078401.0,Stocks That Hit 52-Week Highs On Friday,2019-12-27 11:27:00-05:00,REPH,neutral
1078402.0,"The Daily Biotech Pulse: Flexion Receives FDA Nod For Zilretta Label Expansion, Astellas Goes Shopping",2019-12-27 07:59:00-05:00,REPH,neutral
1078403.0,"The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering",2019-12-20 08:12:00-05:00,REPH,positive
1078404.0,Stocks That Hit 52-Week Highs On Thursday,2019-12-19 10:29:00-05:00,REPH,neutral
1078405.0,"The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug",2019-12-04 07:06:00-05:00,REPH,negative
1078406.0,Stocks That Hit 52-Week Highs On Tuesday,2019-12-03 10:13:00-05:00,REPH,neutral
1078407.0,"The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial",2019-12-03 07:59:00-05:00,REPH,neutral
1078408.0,Stocks That Hit 52-Week Highs On Friday,2019-11-29 10:28:00-05:00,REPH,neutral
1078409.0,"Stephens & Co. Maintains Overweight on Recro Pharma, Lowers Price Target to $19",2019-11-26 07:44:00-05:00,REPH,negative
1078410.0,"The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate",2019-11-22 08:18:00-05:00,REPH,positive
1078411.0,"The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing",2019-11-14 08:07:00-05:00,REPH,positive
1078412.0,Stocks That Hit 52-Week Highs On Wednesday,2019-11-13 10:12:00-05:00,REPH,neutral
1078413.0,Stocks That Hit 52-Week Highs On Friday,2019-11-08 10:30:00-05:00,REPH,neutral
1078414.0,"The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings",2019-11-06 08:21:00-05:00,REPH,positive
1078415.0,Stocks That Hit 52-Week Highs On Tuesday,2019-11-05 11:12:00-05:00,REPH,neutral
1078416.0,"Recro Pharma Board Approves Separation Of Acute Care Business Unit; Declares Special Dividend For Baudax Bio Common Stock: For Every 2.5 Shares Of Recro, Shareholders Will Receive 1 Share Of Baudax",2019-11-05 07:53:00-05:00,REPH,positive
1078417.0,"The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment",2019-11-05 06:53:00-05:00,REPH,negative
1078418.0,Stocks That Hit 52-Week Highs On Monday,2019-11-04 14:43:00-05:00,REPH,neutral
1078419.0,Stocks That Hit 52-Week Highs On Friday,2019-11-01 10:31:00-04:00,REPH,neutral
1078420.0,"The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance",2019-11-01 07:38:00-04:00,REPH,neutral
1078421.0,FDA Grants Appeal to Recro Pharma for IV Meloxicam New Drug Application,2019-10-31 08:14:00-04:00,REPH,positive
1078422.0,Stocks That Hit 52-Week Highs On Wednesday,2019-10-30 10:35:00-04:00,REPH,neutral
1078423.0,Stocks That Hit 52-Week Highs On Friday,2019-10-25 12:47:00-04:00,REPH,neutral
1078424.0,Stocks That Hit 52-Week Highs On Monday,2019-10-21 11:06:00-04:00,REPH,neutral
1078425.0,"Benzinga's Top Upgrades, Downgrades For October 17, 2019",2019-10-17 09:37:00-04:00,REPH,positive
1078426.0,"Stephens & Co. Initiates Coverage On Recro Pharma with Overweight Rating, Announces $14 Price Target",2019-10-17 07:49:00-04:00,REPH,negative
1078427.0,Stocks That Hit 52-Week Highs On Thursday,2019-08-22 10:32:00-04:00,REPH,neutral
1078428.0,"The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study",2019-08-22 07:18:00-04:00,REPH,positive
1078429.0,Stocks That Hit 52-Week Highs On Wednesday,2019-08-14 12:05:00-04:00,REPH,neutral
1078430.0,"The Daily Biotech Pulse: Vascepa Delay Sends Amarin Reeling, Eidos Jumps On Buyout Offer, Nektar's Bitter Q2",2019-08-09 07:19:00-04:00,REPH,negative
1078431.0,Stocks That Set New 52-Week Highs Thursday,2019-08-08 12:19:00-04:00,REPH,neutral
1078432.0,"Recro Pharma Reports Plan To Spin Out Acute Care Segment, Have CDMO Business, Acute Care Business Operate As 2 Separately Traded Public Cos.",2019-08-08 07:19:00-04:00,REPH,positive
1078433.0,Recro Pharma Raises FY19 Sales Guidance From $85M-$87M To $91M-$94M vs $91.3M Estimate,2019-08-08 07:19:00-04:00,REPH,neutral
1078434.0,"Recro Pharma Q2 EPS $(0.13) Beats $(0.42) Estimate, Sales $31.3M Beat $23.59M Estimate",2019-08-08 07:18:00-04:00,REPH,neutral
1078435.0,"The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales",2019-05-10 08:00:00-04:00,REPH,negative
1078436.0,"Recro Pharma Q1 EPS $(0.10) vs $(0.65) In Same Qtr. Last Year, Sales $25.065M Beat $20.51M Estimate",2019-05-10 07:25:00-04:00,REPH,neutral
1078437.0,Recro Pharma Announces Six-Year Extension of License and Supply Agreement Between Teva and Recro Gainesville,2019-04-16 07:05:00-04:00,REPH,positive
1078438.0,Recro Pharma Highlights Presentation Of New Meta-Analysis For IV Meloxicam At The 44th Annual Regional Anesthesiology And Acute Pain Medicine Meeting,2019-04-11 16:06:00-04:00,REPH,negative
1078439.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Fri., Apr. 5, 2019",2019-04-05 10:03:00-04:00,REPH,positive
1078440.0,52 Biggest Movers From Yesterday,2019-04-05 05:55:00-04:00,REPH,neutral
1078441.0,Mid-Afternoon Market Update: Dow Up 135 Points; Recro Pharma Shares Spike Higher,2019-04-04 14:36:00-04:00,REPH,positive
1078442.0,44 Stocks Moving In Thursday's Mid-Day Session,2019-04-04 12:39:00-04:00,REPH,neutral
1078443.0,Mid-Day Market Update: Resources Connection Falls After Q3 Results; Tonix Pharmaceuticals Shares Surge,2019-04-04 12:12:00-04:00,REPH,positive
1078444.0,Mid-Morning Market Update: Markets Open Higher; Constellation Brands Tops Q4 Estimates,2019-04-04 10:08:00-04:00,REPH,positive
1078445.0,"Recro Pharma shares are trading higher after the company raised FY19 sales guidance from $80 million to $85-$87 million, compared to the $85.12 million estimate; the company also announced a reorganization plan in its acute care segment.",2019-04-04 09:25:00-04:00,REPH,positive
1078446.0,32 Stocks Moving In Thursday's Pre-Market Session,2019-04-04 08:18:00-04:00,REPH,neutral
1078447.0,"The Daily Biotech Pulse: Recro Restructures, Biotechs Raise Proceeds In Droves, Silk Road, NGM Biopharma To Debut",2019-04-04 07:58:00-04:00,REPH,neutral
1078448.0,Recro Pharma shares are trading higher after the company announced a reorganization plan in its acute care segment and raised FY19 sales guidance.,2019-04-03 17:14:00-04:00,REPH,positive
1078449.0,Recro Pharma Raises FY19 Sales Guidance From $80M To $85M-$87M vs $85.12M,2019-04-03 16:09:00-04:00,REPH,neutral
1078450.0,"Recro Pharma Restructures Acute Care Segment, Plans To Reduce Staff",2019-04-03 16:08:00-04:00,REPH,positive
1078451.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs",2019-03-30 09:32:00-04:00,REPH,neutral
1078452.0,52 Biggest Movers From Yesterday,2019-03-26 05:04:00-04:00,REPH,neutral
1078453.0,Mid-Afternoon Market Update: DarioHealth Falls Following Q4 Results; Avaya Shares Jump,2019-03-25 14:31:00-04:00,REPH,positive
1078454.0,41 Stocks Moving In Monday's Mid-Day Session,2019-03-25 12:51:00-04:00,REPH,neutral
1078455.0,Mid-Day Market Update: Iterum Therapeutics Gains After Q4 Results; Proteostasis Therapeutics Shares Slide,2019-03-25 12:32:00-04:00,REPH,positive
1078456.0,More Pain For Recro Pharma: FDA Rejects Meloxicam NDA For Second Time,2019-03-25 10:53:00-04:00,REPH,negative
1078457.0,Mid-Morning Market Update: Markets Open Lower; Winnebago Industries Posts Mixed Q4 Results,2019-03-25 10:27:00-04:00,REPH,negative
1078458.0,Recro Pharma shares are trading lower after the company's marketing application for IV Meloxicam was rejected by the FDA.,2019-03-25 09:08:00-04:00,REPH,negative
1078459.0,"Roth Capital Downgrades Recro Pharma to Neutral, Announces $7.50",2019-03-25 08:39:00-04:00,REPH,neutral
1078460.0,30 Stocks Moving In Monday's Pre-Market Session,2019-03-25 08:11:00-04:00,REPH,neutral
1078461.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs",2019-03-23 12:20:00-04:00,REPH,neutral
1078462.0,Recro Pharma Receives CRLfrom the FDA for IV Meloxicam,2019-03-22 15:32:00-04:00,REPH,neutral
1078463.0,Recro Pharma Shares Halted News Pending,2019-03-22 15:25:00-04:00,REPH,positive
1078464.0,Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates,2019-03-04 11:50:00-05:00,REPH,neutral
1078465.0,"Recro Pharma Highlights Publication Of Phase III IV Meloxicam Safety, Opioid Use Data In Journal Clinical Pharmacology in Drug Development",2019-02-25 17:02:00-05:00,REPH,positive
1078466.0,Recro Pharma Announces New IV Meloxicam Data Publication In The Journal Regional Anesthesia & Pain Medicine,2019-02-20 07:25:00-05:00,REPH,negative
1078467.0,Recro Pharma Files For $100M Mized Shelf Offering,2019-02-19 10:10:00-05:00,REPH,neutral
1078468.0,"Recro Pharma Q4 EPS $(1.92) Misses $(0.75) Estimate, Sales $17.78M Beat $16.05M Estimate",2019-02-19 07:23:00-05:00,REPH,negative
1078469.0,Recro Pharma Announces a 5 Year Supply Contract with Novartis Pharma,2019-02-11 07:18:00-05:00,REPH,neutral
1078470.0,Janney Capital Assumes Recro Pharma at Buy,2019-01-31 08:35:00-05:00,REPH,neutral
1078471.0,Recro Pharma Amends IV Meloxicam License Agreement With Alkermes,2018-12-21 07:02:00-05:00,REPH,positive
1078472.0,Recro Pharma Sees FY2018 Sales $75.0M vs $73.46M Est,2018-11-07 08:26:00-05:00,REPH,neutral
1078473.0,"Recro Pharma Q3 EPS $(0.64) Beats $(0.70) Estimate, Sales $18.283M Beat $16.73M Estimate",2018-11-07 08:25:00-05:00,REPH,neutral
1078474.0,"The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie",2018-11-07 07:50:00-05:00,REPH,negative
1078475.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,REPH,neutral
1078476.0,"Recro Pharma Announces the FDA Set a PDUFA Date of March 24, 2019 for Recro's New Drug Application for Intravenous Meloxicam",2018-10-08 07:03:00-04:00,REPH,neutral
1078477.0,54 Biggest Movers From Yesterday,2018-09-06 05:13:00-04:00,REPH,neutral
1078478.0,55 Biggest Movers From Yesterday,2018-09-05 04:48:00-04:00,REPH,neutral
1078479.0,38 Stocks Moving In Tuesday's Mid-Day Session,2018-09-04 13:49:00-04:00,REPH,neutral
1078480.0,Mid-Morning Market Update: Markets Open Lower; Conn's Profit Tops Estimates,2018-09-04 10:38:00-04:00,REPH,positive
1078481.0,"Recro Pharma shares are up 21.2% after the company announced it plans to resubmit a New Drug Application (NDA) for postoperative pain management therapy, IV meloxicam.",2018-09-04 10:28:00-04:00,REPH,negative
1078482.0,"After Type A Meeting With FDA, Recro Pharma Now Anticipates Resubmitting NDA For IV Meloxicam By The End Of September; NDA Will Incorporate Revised Language Relating To Product And Label",2018-09-04 07:04:00-04:00,REPH,neutral
1078483.0,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",2018-08-07 08:23:00-04:00,REPH,negative
1078484.0,"Recro Pharma Q2 EPS $(0.62) Beats $(1.34) Estimate, Sales $21.739M Beat $16.66M Estimate",2018-08-07 07:25:00-04:00,REPH,neutral
1078485.0,Recro Pharma Q2 Earnings Preview,2018-08-06 15:39:00-04:00,REPH,neutral
1078486.0,"Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos",2018-06-29 08:11:00-04:00,REPH,positive
1078487.0,Recro Pharma Reports Publication of Phase III IV Meloxicam Abdominoplasty Data in Plastic and Reconstructive Surgery Global Open Journal,2018-06-26 07:01:00-04:00,REPH,neutral
1078488.0,"Benzinga's Weekly Movers For The Week Of May 25, 2018",2018-05-25 16:54:00-04:00,REPH,neutral
1078489.0,"Benzinga's Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck's Cancer Drug Review Extended",2018-05-25 09:19:00-04:00,REPH,negative
1078490.0,26 Stocks Moving In Friday's Pre-Market Session,2018-05-25 08:15:00-04:00,REPH,neutral
1078491.0,45 Biggest Movers From Yesterday,2018-05-25 04:37:00-04:00,REPH,neutral
1078492.0,Mid-Afternoon Market Update: Crude Oil Down Over 1%; Recro Pharma Shares Slide,2018-05-24 15:23:00-04:00,REPH,negative
1078493.0,42 Stocks Moving In Thursday's Mid-Day Session,2018-05-24 13:31:00-04:00,REPH,neutral
1078494.0,Mid-Day Market Update: Westell Drops Following Weak Q4 Earnings; Destination Maternity Shares Climb,2018-05-24 12:15:00-04:00,REPH,negative
1078495.0,Mid-Morning Market Update: Markets Open Lower; McKesson Earnings Miss Estimates,2018-05-24 10:11:00-04:00,REPH,negative
1078496.0,FDA Declines Recro's IV Meloxicam Application,2018-05-24 10:11:00-04:00,REPH,neutral
1078497.0,Recro Pharma Shares Down 50.1% Premarket After FDA Issued CRL Saying It Could Not Approve IV Meloxicam In Its Current Form,2018-05-24 08:43:00-04:00,REPH,positive
1078498.0,25 Stocks Moving In Thursday's Pre-Market Session,2018-05-24 08:40:00-04:00,REPH,neutral
1078499.0,"Recro Pharma Shares Resume Trade, Down 57.7%",2018-05-24 07:34:00-04:00,REPH,positive
1078500.0,Recro Pharma Shares To Resume Trade At 7:30 p.m. EDT,2018-05-24 07:06:00-04:00,REPH,positive
1078501.0,"Recro Pharma Receives Complete Response Letter from the FDA,Company to Host Conference Call Today at 8:00 AM ET",2018-05-24 07:01:00-04:00,REPH,neutral
1078502.0,Recros Pharma Shares Halted News Pending,2018-05-24 06:56:00-04:00,REPH,positive
1078503.0,"Benzinga's Daily Biotech Pulse: Insmed Presents Data, Pfenex Pulls Back On Offering, Oncolytics Listing",2018-05-23 08:15:00-04:00,REPH,neutral
1078504.0,"The Week Ahead In Biotech: PDUFA Dates, IPOs And More",2018-05-21 07:40:00-04:00,REPH,neutral
1078505.0,"Recro Pharma Q1 EPS $(0.65) Beats $(0.70) Estimate, Sales $19.54M Beat $17.74M Estimate",2018-05-09 07:04:00-04:00,REPH,neutral
1078506.0,Recro Pharma Announces Receipt of Issue Notifications for Three New Patents for IV Meloxicam,2018-05-07 07:07:00-04:00,REPH,neutral
1078507.0,Attention Biotech Investors: Mark Your Calendar For These May PDUFA Action Dates,2018-05-01 15:39:00-04:00,REPH,neutral
1078508.0,"Recro Pharma CEO Talks Non-Opioid Pain Management Opportunity, CDMO Business",2018-04-05 09:28:00-04:00,REPH,negative
1078509.0,45 Biggest Movers From Yesterday,2018-03-02 05:03:00-05:00,REPH,neutral
1078510.0,34 Stocks Moving In Thursday's Mid-Day Session,2018-03-01 12:43:00-05:00,REPH,neutral
1078511.0,"Oppenheimer Initiates Coverage On Recro Pharma with Outperform Rating, Announces $19.00 Price Target",2018-02-14 09:03:00-05:00,REPH,neutral
1078512.0,Recro Pharma Announces Michael Celano COO and Ryan Lake CFO,2018-01-03 07:08:00-05:00,REPH,neutral
1078513.0,Recro Pharma Raises FY17 Sales From $60-$63M To $65M,2017-11-09 07:09:00-05:00,REPH,neutral
1078514.0,"Recro Pharma Reports Q3 EPS $(0.48) vs $(0.75) Est., Sales $17.11M vs $13.68M Est.",2017-11-09 07:08:00-05:00,REPH,neutral
1078515.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-10-10 08:08:00-04:00,REPH,neutral
1078516.0,"Recro Pharma Offers Phase III IV Meloxicam Efficacy Data In Patients Following Abdominoplasty: 30mg Showed 'Statistically Significant Reductions in Pain, Along with Reductions in Opioid Rescue Use and Improvements in Several Other Pain Relief Metrics'",2017-10-10 07:03:00-04:00,REPH,positive
1078517.0,"Recro Pharma Reports PDUFA Date For IV Meloxicam 30mg As May 26, 2018",2017-10-05 07:08:00-04:00,REPH,neutral
1078518.0,Recro Pharma Reports FDA Acceptance For Review Of NDA For IV Meloxicam 30mg,2017-09-28 07:03:00-04:00,REPH,positive
1078519.0,"Recro Pharma Reports Q2 EPS $(0.48) vs $(0.53) Est., Sales $16.934M vs $14.6M Est.",2017-08-10 07:17:00-04:00,REPH,neutral
1078520.0,Recro Pharma Submits NDA to the FDA for Meloxicam,2017-07-31 07:14:00-04:00,REPH,neutral
1078521.0,Recro Pharma Submits NDA for IV Meloxicam 30mg,2017-07-31 07:01:00-04:00,REPH,neutral
1078522.0,"Recro Pharma Reports Purchase Of Novel Neuromuscular Blocking Agents, Proprietary Chemical Reversal Agent From Cornell, Terms Not Disclosed",2017-07-05 08:34:00-04:00,REPH,negative
1078523.0,"Recro Pharma Acquires Novel Neuromuscular Blocking Agents from Cornell, Terms not Disclosed",2017-07-05 08:02:00-04:00,REPH,negative
1078524.0,"Recro Pharma Offers Poster Presentation Ahead of American Pain Society Meeting, Highlights 'Clinical Performance of IV Meloxicam 30mg, Including Statistically Significant Differences in SPID48 and Numerous Other Rescue Use and Pain Relief Metrics'",2017-05-18 08:09:00-04:00,REPH,positive
1078525.0,Exclusive: Recro Pharma CEO Talks Meloxicam Non-Opioid Product Ahead Of APS Annual Meeting,2017-05-17 11:15:00-04:00,REPH,positive
1078526.0,"Recro Pharma Reports Q1 EPS $(0.42) vs $(0.58) Est., Sales $18.7M vs $15.1M Est.",2017-05-11 07:07:00-04:00,REPH,neutral
1078527.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-05-09 08:16:00-04:00,REPH,neutral
1078528.0,UPDATE: Recro Pharma Says Co. On Track to File NDA for IV Meloxicam in Early Q3'17,2017-05-09 07:56:00-04:00,REPH,neutral
1078529.0,Recro Pharma Announces Successful Top-Line Results from Phase III Safety Study of IV Meloxicam,2017-05-09 07:14:00-04:00,REPH,positive
1078530.0,"Recro Pharma Says, with Q4, FY16 Earnings Report, On Track to File NDA with FDA for IV Meloxicam in Summer '17",2017-03-06 16:39:00-05:00,REPH,neutral
1078531.0,Recro Pharma Sees FY17 Sales $55M-$60M vs $60M Est.,2017-03-06 16:21:00-05:00,REPH,neutral
1078532.0,"Recro Pharma Reports FY16 EPS $(2.82) vs $(2.94) Est., Sales $69.337M vs $65.3M Est.",2017-03-06 16:11:00-05:00,REPH,neutral
1078533.0,"Exclusive: Recro Pharma CEO Talks Meloxicam, Alleviating Investor Concerns",2017-01-18 14:50:00-05:00,REPH,positive
1078534.0,15 Biggest Mid-Day Gainers For Monday,2016-12-19 12:43:00-05:00,REPH,neutral
1078535.0,"Benzinga's Top Upgrades, Downgrades For December 19, 2016",2016-12-19 09:08:00-05:00,REPH,positive
1078536.0,"PiperJaffray Initiates Coverage On Recro Pharma at Overweight, Announces $12.00 Target",2016-12-19 07:47:00-05:00,REPH,negative
1078537.0,"Deerfield Mgmt, L.P. Reports 10.9% Passive Stake in Recro Pharma in 13G",2016-12-16 15:51:00-05:00,REPH,positive
1078538.0,Recro Pharma Prices 6.5M Offering At $6/Share,2016-12-13 09:13:00-05:00,REPH,neutral
1078539.0,10 Stocks With Lowest Close In Three Weeks,2016-12-13 06:45:00-05:00,REPH,negative
1078540.0,"Former Insys Execs Charged With Bribery, Racketeering",2016-12-08 15:18:00-05:00,REPH,negative
1078541.0,Recro Pharma Announces Proposed Public Offering of Common Stock,2016-12-08 09:02:00-05:00,REPH,neutral
1078542.0,Recro Pharma Enters into Amendment to Purchase and Sale Agreement with Alkermes; Recro May Defer Milestone Payment Until Approval of NDA for Intravenous Meloxicam,2016-12-08 06:39:00-05:00,REPH,positive
1078543.0,Recro Pharma Shares Down 14% On Earlier S-1 Filing Showing $57.5M Offering,2016-12-01 14:05:00-05:00,REPH,positive
1078544.0,Recro Pharma CEO Discusses Strong Results In Non-Opioid Pain Treatment Study,2016-12-01 10:49:00-05:00,REPH,neutral
1078545.0,Mid-Afternoon Market Update: Fang Holdings Drops Following Q3 Results; Recro Pharma Shares Surge,2016-11-28 14:36:00-05:00,REPH,positive
1078546.0,12 Biggest Mid-Day Gainers For Monday,2016-11-28 12:47:00-05:00,REPH,neutral
1078547.0,Mid-Day Market Update: Crude Oil Up Over 2%; PhaseRx Shares Spike Higher,2016-11-28 12:08:00-05:00,REPH,negative
1078548.0,Recro's Late-Stage IV Meloxicam Trial Results Rocket Stock Skyward,2016-11-28 10:42:00-05:00,REPH,neutral
1078549.0,"Roth Out Positive On Recro Pharma, Increases Probability From ~50% Chance To 75% Of IV meloxicam Approval; Would Add ~$5-7/Share Increase In PT",2016-11-28 10:11:00-05:00,REPH,positive
1078550.0,Mid-Morning Market Update: Markets Open Lower; Edwards Lifesciences To Buy Valtech Cardio,2016-11-28 09:56:00-05:00,REPH,negative
1078551.0,"Recro Pharma Reports Positive Top-Line Results from Pivotal Phase III Clinical Trial of IV Meloxicam, Achieves Primary Endpoint And 10 Secondary Endpoints; Estimates USNDA Filing Summer 2017",2016-11-28 07:03:00-05:00,REPH,positive
1078552.0,"Recro Pharma Reports Q3 EPS $(0.50) vs. Est. $(0.71), Rev. $19.5M vs. Est. $13.5M",2016-11-10 07:21:00-05:00,REPH,neutral
1078553.0,Recro Pharma Offers A Non-Opioid Alternative For Pain Management; Brean Assumes With Buy Rating,2016-10-03 10:34:00-04:00,REPH,negative
1078554.0,Benzinga's   Top Initiations,2016-10-03 09:33:00-04:00,REPH,positive
1078555.0,"Brean Capital Assumes Recro Pharma at Buy, Announces $21.00 PT",2016-10-03 06:14:00-04:00,REPH,neutral
1078556.0,Roth Capital Initiates Coverage on Recro Pharma at Buy,2016-09-16 08:53:00-04:00,REPH,neutral
1078557.0,Recro Pharma Releases Slide Presentation,2016-09-12 07:48:00-04:00,REPH,neutral
1078558.0,Benzinga's Top Initiations,2016-08-29 08:59:00-04:00,REPH,positive
1078559.0,Janney Capital Initiates Coverage on Recro Pharma at Buy,2016-08-29 06:19:00-04:00,REPH,neutral
1078560.0,Recro Pharma Prices Offering of ~1.987M Shares at $7.50/Share,2016-08-16 09:00:00-04:00,REPH,positive
1078561.0,Recro Pharma Announces Proposed Public Offering of Common Stock,2016-08-15 18:06:00-04:00,REPH,neutral
1078562.0,"Recro Pharma Reports Q2 EPS $(0.83) vs. Est. (0.78), Rev. $17.27M vs. Est. $15.4M",2016-08-11 07:03:00-04:00,REPH,neutral
1078563.0,18 Biggest Mid-Day Gainers For Wednesday,2016-07-27 12:10:00-04:00,REPH,neutral
1078564.0,18 Stocks Moving In Wednesday's Pre-Market Session,2016-07-27 08:33:00-04:00,REPH,neutral
1078565.0,Recro Pharma Shares Up 51% Upon Resumption,2016-07-26 16:37:00-04:00,REPH,positive
1078566.0,Recro Pharma Shares to Resume Trade 4:35 p.m. EDT,2016-07-26 16:13:00-04:00,REPH,positive
1078567.0,"Recro Pharma Reports Top-Line Results from Phase III Trial of IV Meloxicam: Met Primary Endpoint, Fifteen of Nineteen Secondary Endpoints Achieved",2016-07-26 16:08:00-04:00,REPH,neutral
1078568.0,Recros Pharma Shares Halted News Pending,2016-07-26 16:04:00-04:00,REPH,positive
1078569.0,Recro Pharma Names Michael Celano CFO,2016-07-05 07:02:00-04:00,REPH,neutral
1078570.0,"Recro Pharma Reports Q1 EPS $(0.71) vs. Est. $(0.66), Rev. $17.7M vs. Est. $13M",2016-05-12 09:17:00-04:00,REPH,neutral
1078571.0,"Recro Pharma Reports FY15 EPS $0.21 vs $(2.79) in Same Qtr. Last Year, Sales $51.952M vs $47.7M Est.",2016-03-24 08:22:00-04:00,REPH,neutral
1078572.0,Recro Pharma Names Fred Graff as Chief Commercial Officer,2016-02-16 08:07:00-05:00,REPH,neutral
1078573.0,Recro Pharma Reports Initiation of Pivotal Phase III Trial of IV Meloxicam for Acute Postoperative Pain,2016-01-27 08:04:00-05:00,REPH,negative
1078574.0,Recro Pharma Reports Meloxicam Well Tolerated with Statistically Significant Analgesic Effect,2016-01-06 07:04:00-05:00,REPH,positive
1078575.0,Recro Pharma Says Co. On Track to Initiate Pivotal Phase III in Q1'16,2016-01-06 07:04:00-05:00,REPH,neutral
1078576.0,Recro Pharma Names Dr. Stewart McCallum Chief Medical Officer,2015-12-02 07:01:00-05:00,REPH,neutral
1078577.0,"Recro Pharma Reports Q3 EPS ($0.24) vs. Est. ($0.20), Rev. $16.539M vs. Est. $15.25M",2015-11-13 07:00:00-05:00,REPH,neutral
1078578.0,"UPDATE: Recro Pharma Announces IV Meloxicam Advancing to Phase III, Pivotal Trials Expected to Commence in Q1'16",2015-10-26 08:01:00-04:00,REPH,neutral
1078579.0,Recro Pharma Issues Pipeline Update,2015-10-26 08:00:00-04:00,REPH,neutral
1078580.0,Non-Opioid Therapeutics And Significant Pain Treatments Make For A Buy Rating,2015-09-02 10:58:00-04:00,REPH,negative
1078581.0,S-3 from Recro Pharma Shows Registration for $100M Mixed Securities Shelf Offering,2015-08-20 17:26:00-04:00,REPH,positive
1078582.0,"Recro Pharma Reports Q2 EPS $(0.17) vs. Est. $(0.03), Rev. $18.66M vs. Est. $15M",2015-08-14 16:25:00-04:00,REPH,neutral
1078583.0,Recro Pharma Reports Additional Information for Phase II Clinical Trial of Dex-IN,2015-07-24 07:02:00-04:00,REPH,neutral
1078584.0,"Market Update: Google & Hertz Among Mid-Day Movers, Germany Votes In Favor Of Greece Bailout And More",2015-07-17 12:16:00-04:00,REPH,positive
1078585.0,Benzinga's Volume Movers,2015-07-17 10:40:00-04:00,REPH,neutral
1078586.0,Morning Market Gainers,2015-07-17 09:51:00-04:00,REPH,neutral
1078587.0,Recro Pharma Reports Positive Top-Line Results for Phase II Clinical Trial of Dex-IN,2015-07-17 08:01:00-04:00,REPH,positive
1078588.0,Form D from Recro Pharma Shows Co. Sold ~$16M in Equity Financing,2015-07-13 14:34:00-04:00,REPH,neutral
1078589.0,Recro Pharma Announces Purchase Agreement  To Issues & Sell 1.379M Shares Of Stock At $11.60/Share For Gross Proceeds Of $16M,2015-07-01 09:17:00-04:00,REPH,positive
1078590.0,"Recro Pharma CEO Henwood Buys 4,500 Shares @$8.92/Share -Form 4",2015-06-09 12:37:00-04:00,REPH,positive
1078591.0,Recro Pharma ProvidesUpdate on Continuing Phase II Clinical Trial of Dex-IN for Treatment of Acute Pain on Day 1 Following Surgery,2015-04-09 07:04:00-04:00,REPH,negative
1078592.0,Recro Pharma Announces Update on On-Going Phase II Clinical Trial of Dex-IN for Treatment of Acute Pain on Day 1 Following Surgery,2015-04-09 07:03:00-04:00,REPH,negative
1078593.0,Morning Market Gainers,2015-03-09 09:43:00-04:00,REPH,neutral
1078594.0,"Recro Pharma to Acquire IV/IM Meloxicam, Gainesville, GA GMP Manufacturing Facility, Business Unit from Alkermes for $50M",2015-03-09 06:01:00-04:00,REPH,neutral
1078595.0,"Recro Pharma In Share Buy Bacl With Aspire For $10M Shares, Recro Can Raise $10M Over 2 Years",2015-02-03 06:16:00-05:00,REPH,positive
1078596.0,Stocks Hitting 52-Week Lows,2014-12-16 10:29:00-05:00,REPH,negative
1078597.0,"Aegis Capital Downgrades Recro Pharma, Says Investors Should Be Cautious",2014-12-09 14:59:00-05:00,REPH,negative
1078598.0,Aegis Capital Downgrades Recro Pharma to Hold,2014-12-09 13:33:00-05:00,REPH,neutral
1078599.0,Recro Pharma Reports Q3 EPS of $(0.61) vs $(0.51) Est,2014-11-10 07:16:00-05:00,REPH,neutral
1078600.0,Recro Pharma Announces Dosing of First Patient in Phase II REC-14-013 Clinical Trial of Dex-IN for Treatment of Acute Pain on Day 1 Following Surgery ,2014-10-29 16:11:00-04:00,REPH,negative
1078601.0,Stocks Hitting 52-Week Lows,2014-09-05 10:02:00-04:00,REPH,negative
1078602.0,Morning Market Losers ,2014-09-05 09:43:00-04:00,REPH,negative
1078603.0,PREVIEW: Recro Pharma to Resume Trading at 5:20 PM ET,2014-09-04 16:58:00-04:00,REPH,neutral
1078604.0,Reco Pharma Says Trial Study Not Seen Reaching Statistical Significance ,2014-09-04 16:52:00-04:00,REPH,positive
1078605.0,"Reco Pharma Shares Halted, News Pending",2014-09-04 16:33:00-04:00,REPH,positive
1078606.0,Recro Pharma Reports Q2 EPS of $(0.36) vs $(0.25) Est,2014-08-12 07:09:00-04:00,REPH,neutral
1078607.0,UPDATE: Recro Pharma Expecting Top-Line Data by End of 2014,2014-06-17 07:31:00-04:00,REPH,neutral
1078608.0,Recro Pharma Announces Dosing of First Patient in Phase IIb Trial of Dex-IN for Treatment of Acute Pain Following Surgery,2014-06-17 07:31:00-04:00,REPH,negative
1078609.0,"Aegis Capital Initiates Coverage Recro Pharma  with Buy Rating, $40 Price Target",2014-06-12 08:43:00-04:00,REPH,neutral
1078610.0,Recro Pharma Reports Q1 EPS of $(3.67) Which May Not Compare $(0.36) Est,2014-05-12 07:32:00-04:00,REPH,neutral
1078611.0,"Recro Pharma Closes IPO, Sees Total Gross Proceeds $34.5M",2014-03-12 16:15:00-04:00,REPH,negative
1078612.0,Recro Pharma Announces Closing of Initial Public Offering,2014-03-12 16:06:00-04:00,REPH,neutral
1078613.0,Shares of Recro Pharma Open for Trade at $8.53 After Pricing at $8/Share,2014-03-07 10:51:00-05:00,REPH,positive
1078614.0,"Waiting on One More IPO This Morning, Recro Pharma: Expected to Open for Trade at 10:50AM EST, Priced 3.75M Shares at $8/Share",2014-03-07 10:41:00-05:00,REPH,positive
